ZorgSaam Ziekenhuis

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Chronic lymphocytic leukaemia4 trials
• Migraine3 trials
• Colorectal cancer2 trials
• Lung cancer2 trials
• Multiple myeloma1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 310 trials
• Phase 23 trials

Status

• Recruiting8 trials
• Active, not recruiting3 trials
• Completed2 trials

Lead sponsor

• AbbVie3 trials
• Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting3 trials
• Stichting Hemato-Oncologie voor Volwassenen Nederland2 trials
• Association NVALT Studies1 trial
• Erasmus Medical Center1 trial
• and 3 more

Running trials

• Recruiting

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· The Netherlands Cancer Institute· Source

• Recruiting

  ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

  NCT07188025· Phase 3· Erasmus Medical Center· Source

• Active, not recruiting

  First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial)

  NCT04639362· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Active, not recruiting

  Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)

  NCT04909684· Phase 3· Stichting Radboud universitair medisch centrum· Source

• Recruiting

  DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  NCT06275958· Phase 3· Leiden University Medical Center· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Enrolling by invitation

  Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

  NCT05707949· Phase 3· AbbVie· Source

• Recruiting

  A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

  NCT05711394· Phase 3· AbbVie· Source

• Active, not recruiting

  Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)

  NCT04597671· Phase 3· Association NVALT Studies· Source

• Recruiting

  REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

  NCT04523428· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Migraine2 recruiting
• Multiple myeloma1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· AbbVie· Source

• Completed

  GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL)

  2024-511048-22-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source